Published in Pharma Law Weekly, January 23rd, 2007
The company has also completed a preliminary analysis of the top-line results of the clinical trial. AZ-003 is an inhalation product candidate being developed for the treatment of patients with acute pain episodes, including patients with breakthrough pain and postoperative pain.
The phase I clinical trial was conducted in opioid naive healthy volunteers in two stages. In Stage 1, the arterial pharmacokinetics (PK) of 25 micrograms of AZ-003 was compared to a 25 micrograms dose of fentanyl administered intravenously (IV)....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.